4//SEC Filing
MESSINA RICHARD 4
Accession 0001209191-18-046792
CIK 0000821995other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 4:22 PM ET
Size
27.6 KB
Accession
0001209191-18-046792
Insider Transaction Report
Form 4
MESSINA RICHARD
Director
Transactions
- Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−13,657$157,056→ 0 total - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−250$2,875→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−250$2,875→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−250$2,875→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−8,000$92,000→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−9,700$111,550→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−41,000$471,500→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−14,500$166,750→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−2,001$23,012→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−28,000$322,000→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−6,250$71,875→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−875$10,063→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−100,000$1,150,000→ 0 total(indirect: See Footnote)
Footnotes (14)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
- [F10]Shares held by Benchmark Pellinore Group.
- [F11]Shares held by SCA Retirement Plan DTD 1/1/91.
- [F12]Shares held by Pamela Brocious M/P PEN PL.
- [F13]Shares held by SCA Money Purchase Plan DTD 1/1/94 Attn Richard Messina.
- [F14]Shares held by The Benchmark Company LLC - Investment Purposes.
- [F2]Includes 5,625 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 5,625 restricted stock units was cancelled in exchange for the Offer Price.
- [F3]Shares held by Richard Messina CF Jacqueline Messina UTMA.
- [F4]Shares held by Richard Messina CF Carolyn Messina UTMA.
- [F5]Shares held by Richard Messina CF Madeline Messina UTMA.
- [F6]Shares held by Equity TR Co TTEE FBO Pamela Brocious SEP.
- [F7]Shares held by Steve A. Sanders and Partners.
- [F8]Shares held by Citistaffing LLC Profit Sharing.
- [F9]Shares held by Summit Capital Associates.
Documents
Issuer
JUNIPER PHARMACEUTICALS INC
CIK 0000821995
Entity typeother
Related Parties
1- filerCIK 0001179382
Filing Metadata
- Form type
- 4
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 4:22 PM ET
- Size
- 27.6 KB